Januvia Generics Arrive In India
MSD Defends Its Turf As Sitagliptin Looks To Unseat Teneligliptin, Vildagliptin
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?
You may also be interested in...
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.
A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.